Elanco CEO: GLP-1s are Driving Animal Protein Use
Summarize this article with:
Live on Bloomberg TVElanco CEO: GLP-1s are Driving Animal Protein UseBloomberg Markets: The CloseDecember 10th, 2025, 12:03 AM GMT+0000Jeff Simmons, CEO of Elanco Animal Health, says the “humanization of pets” is driving growth. He tells Romaine Bostick and Katie Greifeld on “The Close” that Elanco’s new medicine, Canilevia Quattro, is taking significant market share and is the fastest blockbuster in the company’s history. (Source: Bloomberg)More From Bloomberg Markets: The Close06:39J.P. Morgan's Laskowitz: Healthy IPOs Good for Private15 minutes ago06:29Allspring Global CEO on Launching ETFs, Private Credit16 minutes ago08:35Accenture, Anthropic Launch New AI Partnership3 hours ago01:29:07Stocks Slip Ahead of Fed Meeting as Treasury Yields Tick Up | The Close 11/8/2025All episodes and clipsBloomberg TechnologyThe only daily news program focused exclusively on technology, innovation and the future of business from San Francisco. Hosted by Emily Chang.More episodes and clips44:09Nvidia Wins US Approval to Sell H200 Chips to China | Bloomberg Tech 12/9/202503:35Fal’s Software Optimizes Nvidia Chips Says CEO05:27Paramount Offering to 'Overpay' for Warner Bros.: Ross Gerber04:18The Antitrust Concerns Around Warner Bros. OffersThe David Rubenstein Show"The David Rubenstein Show: Peer-to-Peer Conversations" explores successful leadership through the personal and professional choices of the most influential people in business.More episodes and clips24:05David Rubenstein Show: Kevin Hassett24:05The David Rubenstein Show: Maria Sharapova24:06The David Rubenstein Show: Justice Anthony Kennedy24:06The David Rubenstein Show: David SolomonSee all shows